TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this study is to determine whether long term treatment with oral erythromycin is effective in the treatment of subjects with Chronic Obstructive Pulmonary Disease (COPD) by reducing the number of exacerbations and the degree of airway inflammation.


Options:
A: Arm Label: Azythromycin (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Prednisolone | Arm Label: Azythromycin (APRIL) and Placebo (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Placebo Prednisolone | Arm Label: Placebo (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Other: Placebo Azithromycin | Arm Label: Placebo (APRIL) and Placebo (OCELOT); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Azithromycin, Drug: Placebo Prednisolone | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Azythromycin (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Prednisolone (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: OTHER; Name: Placebo Azithromycin; Assigned to Arm(s): Placebo (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Placebo Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Placebo (OCELOT)
B: Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Moxifloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moxifloxacin | Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxycycline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents
Brief Summary: The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colesevelam hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents
Brief Summary: The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Patient Decision Aids for Faecal Occult Blood Test Screening
Brief Summary: This project has been completed and consisted of a randomised trial of six tailored decision aids giving patients evidence-based information about faecal occult blood test screening for bowel cancer. 314 Australians aged between 50-74 years were recruited from five general practices and randomised to received either the tailored decision aid with age-gender and family history specific information and values clarification exercise or a standard government information sheet.

The decision aid significantly increased the proportion of people who were informed participants in the screening program.


Options:
A: Arm Label: 1 Patient decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: 1 Patient decision aid, Behavioral: 2 Usual care | Arm Label: 2 Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 Usual care | Intervention Type: BEHAVIORAL; Name: 1 Patient decision aid; Assigned to Arm(s): 1 Patient decision aid | Intervention Type: BEHAVIORAL; Name: 2 Usual care; Assigned to Arm(s): 1 Patient decision aid, 2 Usual care
B: Arm Label: Decision aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision aid
C: Intervention Type: OTHER; Name: informational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant - Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)
Brief Summary: To compare the change in renal function between CsA or MMF withdrawal from before to 12 months after drug withdrawal in renal transplant recipients on triple immunosuppressive therapy


Options:
A: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
B: Arm Label: Tacrolimus Withdrawal Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: rapamune, mycophenolate mofetil and steroid | Arm Label: Tacrolimus Minimization Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus, sirolimus and steroid | Intervention Type: DRUG; Name: rapamune, mycophenolate mofetil and steroid; Assigned to Arm(s): Tacrolimus Withdrawal Arm | Intervention Type: DRUG; Name: tacrolimus, sirolimus and steroid; Assigned to Arm(s): Tacrolimus Minimization Arm
C: Arm Label: Standard dose EC-MPS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS), Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: High EC-MPS; Type: EXPERIMENTAL; Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS), Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Enteric-coated mycophenolate sodium (EC-MPS); Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS
D: Intervention Type: DRUG; Name: Mycophenolate mofetil withdrawal; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cyclosporione A withdrawal; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multicenter, Randomized, Double-Blind Study Comparing Safety and Efficacy of Norepinephrine Plus Dobutamine Versus Epinephrine Alone in Septic Shock.
Brief Summary: Catecholamines infusion is a major component of septic shock management. International guidelines recommend that norepinephrine should be preferred to epinephrine, though phase III trials are lacking. The present study aimed at comparing the efficacy and safety of norepinephrine plus dobutamine to that of epinephrine in adults with septic shock.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Goal Directed Therapy; Type: EXPERIMENTAL; Interventions: Other: Early Goal Directed Therapy (EGDT) | Intervention Type: OTHER; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): Early Goal Directed Therapy
B: Arm Label: continuous terlipressin; Type: EXPERIMENTAL; Interventions: Drug: continuous infusion of terlipressin | Arm Label: vasopressin; Type: EXPERIMENTAL; Interventions: Drug: Arginine vasopressin | Arm Label: terlipressin bolus dose; Type: EXPERIMENTAL; Interventions: Drug: terlipressin bolus administration | Intervention Type: DRUG; Name: continuous infusion of terlipressin; Assigned to Arm(s): continuous terlipressin | Intervention Type: DRUG; Name: Arginine vasopressin; Assigned to Arm(s): vasopressin | Intervention Type: DRUG; Name: terlipressin bolus administration; Assigned to Arm(s): terlipressin bolus dose
C: Arm Label: Dopamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine | Arm Label: Norepinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Dopamine; Assigned to Arm(s): Dopamine | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): Norepinephrine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: norepinephrine and dobutamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epinephrine plus placebo of dobutamine | Intervention Type: DRUG; Name: norepinephrine and dobutamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: epinephrine plus placebo of dobutamine; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Extension of the Phase II/III Clinical Trial of Intravitreal Triamcinolone on the Effects and Safety of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment
Brief Summary: This open label extension will treat all the eyes of study participants with active study medication (intravitreal triamcinolone) as well as standard laser treatment where appropriate.

The specific aims will be to test the following hypotheses:

* That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment remains efficacious over five years
* That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment retains a manageable and acceptable safety profile over five years


Options:
A: Intervention Type: DRUG; Name: Triamcinolone acetate; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of Care Group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 1mg triamcinolone acetonide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: 4mg triamcinolone acetonide | Intervention Type: PROCEDURE; Name: Standard of Care Group; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 1mg triamcinolone acetonide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: 4mg triamcinolone acetonide; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone Acetonide | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Procedure: Standard of care laser photocoagulation | Intervention Type: DRUG; Name: fluocinolone acetonide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluocinolone Acetonide; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Standard of care laser photocoagulation; Assigned to Arm(s): 3
D: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Electrical Stimulation for Footdrop in Hemiparesis
Brief Summary: The objective of this research is to determine if electrical stimulation can improve the strength and coordination of the lower limb muscles, and the walking ability of stroke survivors.

The knowledge gained from this study may lead to enhancements in the quality of life of stroke survivors by improving their neurological recovery and mobility. The results may lead to substantial changes in the standard of care for the treatment of lower limb hemiparesis after stroke.


Options:
A: Arm Label: Ankle-Foot Orthosis (AFO); Type: ACTIVE_COMPARATOR; Interventions: Other: Ankle-Foot Orthosis (AFO) | Arm Label: WalkAide; Type: ACTIVE_COMPARATOR; Interventions: Device: WalkAide | Intervention Type: DEVICE; Name: WalkAide; Assigned to Arm(s): WalkAide | Intervention Type: OTHER; Name: Ankle-Foot Orthosis (AFO); Assigned to Arm(s): Ankle-Foot Orthosis (AFO)
B: Arm Label: IpsiHand; Type: EXPERIMENTAL; Interventions: Device: IpsiHand Device | Intervention Type: DEVICE; Name: IpsiHand Device; Assigned to Arm(s): IpsiHand
C: Arm Label: Device-assisted rehabilitation; Type: EXPERIMENTAL; Interventions: Device: Electrical Stimulation; Rehabilitation Robot | Intervention Type: DEVICE; Name: Electrical Stimulation; Rehabilitation Robot; Assigned to Arm(s): Device-assisted rehabilitation
D: Arm Label: ODFS; Type: EXPERIMENTAL; Interventions: Device: Odstock Dropped-Foot Stimulator (ODFS), Procedure: Traditional Physical Therapy Treatment | Arm Label: Standard of Care (inc. AFO); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Standard of Care, Procedure: Traditional Physical Therapy Treatment | Intervention Type: DEVICE; Name: Odstock Dropped-Foot Stimulator (ODFS); Assigned to Arm(s): ODFS | Intervention Type: OTHER; Name: Conventional Standard of Care; Assigned to Arm(s): Standard of Care (inc. AFO) | Intervention Type: PROCEDURE; Name: Traditional Physical Therapy Treatment; Assigned to Arm(s): ODFS, Standard of Care (inc. AFO)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Asthma Patient Education (TAPE)
Brief Summary: The purpose of this research study is to investigate the way that educational approaches and presentation of a drug may affect the response to montelukast and placebo (an inactive medication) in subjects with asthma.


Options:
A: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Combivent® CFC MDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Albuterol HFA MDI; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of 2 TeleComputer Diet Change Maintenance Programs
Brief Summary: The purpose of this study is to test two different approaches to helping individuals who have recently starting eating a healthful diet maintain those healthy changes. This study will deliver a health program using an automated telephone system. The programs will be designed to help individuals maintain a healthy diet change for a lifetime.


Options:
A: Arm Label: 1 concurrent smoking cessation; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral counseling plus contingency management | Arm Label: 2 deferred smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral counseling plus contingency management | Intervention Type: BEHAVIORAL; Name: behavioral counseling plus contingency management; Assigned to Arm(s): 1 concurrent smoking cessation, 2 deferred smoking cessation
B: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
C: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring
D: Arm Label: social cognitive theory; Type: EXPERIMENTAL; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Goal Systems Theory; Type: EXPERIMENTAL; Interventions: Behavioral: goal system theory | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): social cognitive theory | Intervention Type: BEHAVIORAL; Name: goal system theory; Assigned to Arm(s): Goal Systems Theory

Answer: D